VAPRISOL-5% DEXTROSE

Dextrose 5%, Conivaptan hydrochloride 0.2mg/1mL, Solution for injection

Marijuana

· Severity: Moderate

· Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.

· Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with conivaptan. Conivaptan is an inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with conivaptan, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

Dextrose 5%, Conivaptan hydrochloride 0.2mg/1mL, Solution for injection

Grapefruit juice

· Severity: Moderate

· Notes for Consumers: In theory, taking large amounts of Grapefruit juice with Conivaptan can increase Conivaptan blood levels. Side effects of Conivaptan could occur. Your health condition will be closely monitored while you are receiving Conivaptan. Promptly report to your health care provider if you experience a fast or pounding heartbeat, muscle weakness, headache, dizziness, faintness, or vomiting after receiving Conivaptan.

· Notes for Professionals: Although not studied, grapefruit juice (food) may interact with conivaptan. Grapefruit juice contains compounds (psoralen derivatives and possibly the flavonoid naringenin) that inhibit the cytochrome P-450 CYP3A4 isozyme in the gut wall. Since conivaptan is metabolized by CYP3A4 isoenzymes, concurrent administration with grapefruit juice could theoretically increase conivaptan serum concentrations. The clinical significance of this potential interaction has not been evaluated.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>